Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma

Heather Landau; Jagadish K Venkata; Yubin Kang; Guenther Koehne; David J Chung; Nikoletta Lendvai; Tricia Bentz; Sergio Giralt

Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma

Heather Landau, Jagadish K Venkata, Yubin Kang, Guenther Koehne, David J Chung, Nikoletta Lendvai, Tricia Bentz, Sergio Giralt

Miami Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Nov 15 2013
Event	Blood - Duration: Jan 1 2020 → …

Conference

Conference	Blood
Period	1/1/20 → …

Disciplines

Medicine and Health Sciences
Immunology and Infectious Disease

Cite this

@conference{34b0f23ba55f499d87a7e061016fc5c6,

title = "Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma",

author = "Heather Landau and Venkata, \{Jagadish K\} and Yubin Kang and Guenther Koehne and Chung, \{David J\} and Nikoletta Lendvai and Tricia Bentz and Sergio Giralt",

note = "Background The alkylating agent melphalan, given at the myeloablative dose of 200mg/m2 preceding autologous hematopoietic stem cell transplantation (AHSCT), is part of the upfront management of patients with multiple myeloma (MM) and has been used in the salvage setting, often as second transplant.; Blood ; Conference date: 01-01-2020",

year = "2013",

month = nov,

day = "15",

language = "American English",

}

TY - CONF

T1 - Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma

AU - Landau, Heather

AU - Venkata, Jagadish K

AU - Kang, Yubin

AU - Koehne, Guenther

AU - Chung, David J

AU - Lendvai, Nikoletta

AU - Bentz, Tricia

AU - Giralt, Sergio

N1 - Background The alkylating agent melphalan, given at the myeloablative dose of 200mg/m2 preceding autologous hematopoietic stem cell transplantation (AHSCT), is part of the upfront management of patients with multiple myeloma (MM) and has been used in the salvage setting, often as second transplant.

PY - 2013/11/15

Y1 - 2013/11/15

UR - http://www.bloodjournal.org/content/122/21/3329/tab-article-info?sso-checked=true

M3 - Presentation

T2 - Blood

Y2 - 1 January 2020

ER -

Phase 1 Trial Of Carfilzomib + High Dose Melphalan Conditioning Regimen Prior To Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Relapsed Multiple Myeloma

Conference

Disciplines

Other files and links

Cite this